About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Maryland | 23,284 Studies Near You | Clareo Health

Clinical Trials LocationsMaryland

Clinical Trials in Maryland

Discover 23,284 clinical trials near Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 8381-8400 of 23,284 trials

Active Not RecruitingPhase 317 miles

Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation

NCT02683889

This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.

University of Colorado, Denver20 participantsStarted Feb 2019

Washington D.C., District of Columbia, United States

COMPLETEDPhase 319 miles

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome

NCT04279314

To investigate the safety and tolerability of long-term treatment with oral trofinetide in girls and women with Rett syndrome

ACADIA Pharmaceuticals Inc.154 participantsStarted Jan 2020

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +18 more locations

Find Trials by Condition in Maryland

Breast Cancerin Maryland Lung Cancerin Maryland Prostate Cancerin Maryland Colorectal Cancerin Maryland Melanomain Maryland Leukemiain Maryland Lymphomain Maryland Pancreatic Cancerin Maryland Ovarian Cancerin Maryland Brain Cancerin Maryland Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 119 miles

A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients

NCT03815695

FT-4202 is an oral small-molecule agonist of pyruvate kinase red blood cell isozyme (PKR) being developed for the treatment of hemolytic anemias. This initial study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of FT-4202 in the context of Phase 1 studies in healthy volunteers and sickle cell disease patients. The effects of food on the absorption of FT-4202 will also be evaluated in healthy volunteers.

Healthy VolunteersSickle Cell Disease

Forma Therapeutics, Inc.130 participantsStarted Dec 2018

Little Rock, Arkansas, United States • Long Beach, California, United States • Oakland, California, United States +15 more locations

COMPLETEDPhase 219 miles

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

NCT00679172

This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility. The vaccine will be delivered as a single oral dose to healthy, typhoid vaccine-naïve adults.

Emergent BioSolutions187 participantsStarted May 2008

South Miami, Florida, United States • Baltimore, Maryland, United States • Burlington, Vermont, United States

RECRUITINGPhase 1/231 miles

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

NCT05519293

This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).

Non-small Cell Lung Cancer

RedCloud Bio76 participantsStarted Dec 2022

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +1 more locations

COMPLETEDNA71 miles

Manual Therapy and Strengthening for the Hip in Older Adults With Chronic Low Back Pain

NCT04009837

Older adults with chronic low back pain (LBP) are at a greater risk for disability, loss of independence, and lower quality of life. Experts agree that LBP is not a homogeneous condition, and treatments should differ based upon clinical presentation. Our past work indicates that all of these hip and lumbar spine impairments may contribute to worse physical function and greater disability, but the relative importance of each impairment is unclear. Thus, clinicians have limited evidence to draw on for treatment decisions for this patient population. We have identified a vulnerable subgroup of older adults with hip and low back pain. The purpose of this study is to randomize participants into one of two treatment arms and analyze the outcomes.

Chronic Low-back PainHip ImpairmentsHip-spine Syndrome+1 more

University of Delaware184 participantsStarted Nov 2019

Newark, Delaware, United States • Durham, North Carolina, United States • Pittsburgh, Pennsylvania, United States

TERMINATEDPhase 1107 miles

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT05484011

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy. Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

Metastatic Pancreatic Adenocarcinoma

HiberCell, Inc.5 participantsStarted Dec 2022

Scottsdale, Arizona, United States • New York, New York, United States • Philadelphia, Pennsylvania, United States +1 more locations

Active Not RecruitingNA159 miles

Safety and Effectiveness Study of the Zenflow Spring System

NCT04987138

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

BPH (Benign Prostatic Hyperplasia)Lower Urinary Tract Symptoms (LUTS)

Zenflow, Inc.279 participantsStarted Sep 2021

Los Angeles, California, United States • Glenview, Illinois, United States • Las Vegas, Nevada, United States +4 more locations

TERMINATEDPhase 2165 miles

A Study of Olaparib and Durvalumab in Prostate Cancer

NCT03810105

The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.

Prostate Cancer

Memorial Sloan Kettering Cancer Center5 participantsStarted Mar 2019

Duarte, California, United States • Chicago, Illinois, United States • Detroit, Michigan, United States +5 more locations

RECRUITINGPhase 1187 miles

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

NCT06361485

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

R3 Stem Cell100 participantsStarted Mar 2024

Scottsdale, Arizona, United States • Beverly Hills, California, United States • New York, New York, United States +1 more locations

UNKNOWNPhase 2187 miles

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

The purpose of this study is to evaluate how safe and effective the combination of the study drugs romidepsin and lenalidomide is for treating patients with peripheral t-cell lymphoma (PTCL) who have not been previously treated for this cancer. Currently, there is no standard treatment for patients with PTCL; the most common treatment used is a combination of drugs called CHOP, but this can be a difficult treatment to tolerate because of side effects, and is not particularly effective for most patients with PTCL. Romidepsin (Istodax®) is a type of drug called an HDAC inhibitor. It interacts with DNA (genetic material in cells) in ways that can stop tumors from growing. It is given as an infusion through the veins. Lenalidomide (Revlimid®) is a type of drug known as an immunomodulatory drug, or IMID for short. This drug affects how tumor cells grow and survive, including affecting blood vessel growth in tumors. It is given as an oral tablet (by mouth).

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+14 more

Northwestern University30 participantsStarted Jun 2015

Duarte, California, United States • New Haven, Connecticut, United States • Chicago, Illinois, United States +2 more locations

TERMINATEDPhase 1/2187 miles

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

NCT01458405

The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.

Myocardial Infarction

Capricor Inc.135 participantsStarted Nov 2012

Birmingham, Alabama, United States • Huntsville, Alabama, United States • La Jolla, California, United States +29 more locations

COMPLETEDPhase 1187 miles

Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL

NCT04524455

The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.

Acute Lymphoblastic Leukemia

Amgen17 participantsStarted Oct 2020

Duarte, California, United States • Chicago, Illinois, United States • New York, New York, United States +16 more locations

COMPLETEDNA212 miles

Evaluation of Product Performance of a New Silicone Hydrogel Multifocal Contact Lens

NCT05660577

The objective of this study is to evaluate the product performance of a new silicone hydrogel daily disposable multifocal contact lens, the Bausch + Lomb (kalifilcon A) Daily Disposable Multifocal Contact Lens, when worn by current soft contact lens wearers on a daily disposable wear basis

Myopia and Hyperopia and Presbyopia

Bausch & Lomb Incorporated301 participantsStarted Nov 2022

San Diego, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

COMPLETEDPhase 1285 miles

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470

This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Efmarodocokin Alfa and to make a preliminary assessment of activity of Efmarodocokin Alfa in combination with standard-of-care (SOC) in the prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

Acute Graft-versus-host Disease

Genentech, Inc.18 participantsStarted Nov 2020

Duarte, California, United States • Los Angeles, California, United States • Miami, Florida, United States +5 more locations

COMPLETEDPhase 1/2346 miles

Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT03848845

This is a phase I/II, single arm, open label, two-part study that will assess safety, tolerability and clinical activity of GSK2857916 given in combination with a programmed cell death-1 (PD-1) inhibitor pembrolizumab in subjects with RRMM. This study will enroll adult subjects with RRMM, who have undergone stem cell transplant or who are considered transplant ineligible. Part 1 is a dose escalation phase to evaluate the safety and tolerability of escalating doses of GSK2857916 in combination with 200 milligrams (mg) pembrolizumab to establish the recommended phase 2 dose (RP2D). The following dose levels of GSK2857916 are planned to be studied: 2.5 milligrams per kilograms (mg/kg) (dose level \[DL\] 1) and 3.4 mg/kg (DL2). Part 2 is a dose expansion cohort. Once the RP2D has been identified, an expansion cohort will open for enrolment to confirm the safety profile and to evaluate the clinical activity of the combination. Up to 40 evaluable subjects will be enrolled in this two-part study (up to 12 in Part 1, and 28 in Part 2).

Multiple Myeloma

GlaxoSmithKline41 participantsStarted Mar 2019

Atlanta, Georgia, United States • Indianapolis, Indiana, United States • Charlotte, North Carolina, United States +9 more locations

TERMINATEDNA377 miles

Pilot Study to Examine the Feasibility of the Dynamic Interferential Spinal Cord Stimulation System™ (DISCSS™)

NCT03341000

This study evaluates use of DISCSS vis SCS. Thirty (30) patients with back pain greater than leg pain who were candidates for Spinal Cord Stimulation (SCS) and have successfully completed a percutaneous trial with a commercially available SCS system will be trialed with a 3-4 day exposure to the investigational DISCSS™ device. The trial will be conducted at 3-5 U.S. centers. The percutaneous trial leads from the commercial system will be connected to the External Pulse Generator of the DISCSS™ Trial System and the patients will be trialed for an additional three-four days.

Meagan Medical18 participantsStarted Dec 2017

Ocala, Florida, United States • Sarasota, Florida, United States • Boston, Massachusetts, United States +2 more locations

TERMINATEDPhase 2424 miles

A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)

NCT03472560

This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.

Non-Small Cell Lung CancerUrothelial Cancer

Pfizer61 participantsStarted May 2018

Glendale, Arizona, United States • Goodyear, Arizona, United States • Phoenix, Arizona, United States +36 more locations

Active Not RecruitingPhase 2/3445 miles

Treatment Effects of Subcutaneous Injections of Pentosan Polysulfate Sodium vs Placebo in Participants With Knee OA Pain

NCT04809376

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared with subcutaneous injections of placebo in participants with knee osteoarthritis pain. Study details include: * The study duration will be up to 31 weeks per participant * The treatment duration will be 6 weeks. * The visit frequency will be twice weekly during treatment. * The visit frequency will be every 4 weeks during the follow-up period.

Osteoarthritis, Knee

Paradigm Biopharmaceuticals USA (INC)602 participantsStarted Oct 2021

Tempe, Arizona, United States • Tempe, Arizona, United States • Tucson, Arizona, United States +30 more locations

RECRUITINGNA1985 miles

Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection

NCT05709184

The goal of this clinical trial is to test whether lyophilized fecal microbime transfer - a dried extract of bacteria from the stool of healthy donors - is better than antibiotic therapy only for treating primary clostridioides difficile infection (CDI) in adult participants. The main question it aims to answer is whether lyophilized fecal microbiome transfer lowers the number of episodes of CDI compared to antibiotic therapy. Participants will be assigned to one of two groups: * In the intervention group participants will be given vancomycin by mouth for five days followed by 5 days of capsules of lyophilized fecal microbiome to swallow, up until day 10. * In the control group participants will be given vancomycin by mouth for ten days. * All participants will be asked to arrive for two follow-up visits and to fill out questionnaires. In addition, all participants will be asked to give stool samples before antibiotic therapy and on the two follow-up visits. Researchers will compare the intervention group and the control group to see if there is a difference in symptoms degree after ten days and in recurrence of the infection after two months. They will also compare side effects, the total use of antibiotics and the change in the composition of bacteria in the stool, namely the presence of bacteria that are resistant to many drugs.

Clostridioides Difficile Infection

Rambam Health Care Campus196 participantsStarted Nov 2023

Edmonton, Canada • Debrecen, Hungary • Haifa, Israel +3 more locations

PreviousPage 420 of 1165Next

in Maryland

Heart Diseasein Maryland